Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140309 · ClinicalTrials.gov registry record · Phase 2
TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment
A Phase 2 study, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
NCT00140309: Completed Phase 2 study, sponsored by Centers for Disease Control and Prevention.
NCT00140309 is a Phase 2 study that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 350 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (163% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00140309, a Phase 2 study, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
Study Summary
This study is a placebo-controlled factorial study, randomized to study drug (moxifloxacin vs. ethambutol) and treatment frequency (daily vs. thrice weekly after an initial two weeks of daily therapy) during the first two months of standard treatment (with isoniazid, rifampin, and pyrazinamide) for sputum smear-positive pulmonary tuberculosis.
Interventions
- DRUG moxifloxacin (with isoniazid, rifampin, pyrazinamide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2003-07 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
What the finished NCT00140309 record still lists
NCT00140309 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (163% higher).
The record links to 0 conditions, and to 1 intervention - of which moxifloxacin (with isoniazid, rifampin, pyrazinamide) is the first listed.
NCT00140309 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00140309 about?
NCT00140309 is a clinical study titled "TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment". This study is a placebo-controlled factorial study, randomized to study drug (moxifloxacin vs. ethambutol) and treatment frequency (daily vs. thrice weekly after an initial two weeks of daily therapy) during the first two months of standard treatment (with isoniazid, rifampin, and pyrazinamide) for ...
What is the current status of trial NCT00140309?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2003-07. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00140309?
The interventions under investigation include: moxifloxacin (with isoniazid, rifampin, pyrazinamide) (DRUG).
Who is sponsoring clinical trial NCT00140309?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00140309's enrollment target sits among peer trials
350 130th of 2000 higher than 1,865 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia